Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
Publication
, Journal Article
Orgel, R; Wojdyla, D; Huberman, D; Halperin, JL; Breithardt, G; Singer, DE; Fox, KAA; Hankey, GJ; Mahaffey, KW; Jones, WS; Patel, MR
Published in: Circ Cardiovasc Qual Outcomes
May 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Circ Cardiovasc Qual Outcomes
DOI
EISSN
1941-7705
Publication Date
May 2017
Volume
10
Issue
5
Location
United States
Related Subject Headings
- Warfarin
- Vitamin K
- Stroke
- Rivaroxaban
- Randomized Controlled Trials as Topic
- Peripheral Nervous System Diseases
- Multicenter Studies as Topic
- Humans
- Factor Xa Inhibitors
- Embolism
Citation
APA
Chicago
ICMJE
MLA
NLM
Orgel, R., Wojdyla, D., Huberman, D., Halperin, J. L., Breithardt, G., Singer, D. E., … Patel, M. R. (2017). Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circ Cardiovasc Qual Outcomes, 10(5). https://doi.org/10.1161/CIRCOUTCOMES.116.003520
Orgel, Ryan, Daniel Wojdyla, David Huberman, Jonathan L. Halperin, Günter Breithardt, Daniel E. Singer, Keith A. A. Fox, et al. “Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).” Circ Cardiovasc Qual Outcomes 10, no. 5 (May 2017). https://doi.org/10.1161/CIRCOUTCOMES.116.003520.
Orgel R, Wojdyla D, Huberman D, Halperin JL, Breithardt G, Singer DE, et al. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circ Cardiovasc Qual Outcomes. 2017 May;10(5).
Orgel, Ryan, et al. “Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).” Circ Cardiovasc Qual Outcomes, vol. 10, no. 5, May 2017. Pubmed, doi:10.1161/CIRCOUTCOMES.116.003520.
Orgel R, Wojdyla D, Huberman D, Halperin JL, Breithardt G, Singer DE, Fox KAA, Hankey GJ, Mahaffey KW, Jones WS, Patel MR. Noncentral Nervous System Systemic Embolism in Patients With Atrial Fibrillation: Results From ROCKET AF (Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Circ Cardiovasc Qual Outcomes. 2017 May;10(5).
Published In
Circ Cardiovasc Qual Outcomes
DOI
EISSN
1941-7705
Publication Date
May 2017
Volume
10
Issue
5
Location
United States
Related Subject Headings
- Warfarin
- Vitamin K
- Stroke
- Rivaroxaban
- Randomized Controlled Trials as Topic
- Peripheral Nervous System Diseases
- Multicenter Studies as Topic
- Humans
- Factor Xa Inhibitors
- Embolism